spacer
home > ict > spring 2018 > exponential developments
PUBLICATIONS
International Clinical Trials

Exponential Developments

“The expected exposure in humans at a dose to be given, in comparison to the exposure at which certain effects were observed in animals or earlier in the study in humans, is considered more relevant than the relative dose levels between animals and humans,” claims the first-in-human (FIH) guidance.

In July 2017, the EMA revised its guidance on FIH clinical trials, providing strategies to identify and mitigate risks for trial participants. This article explores how modern clinical study strategies can be utilised in early phase studies to not only satisfy the new regulatory risk mitigation guidance principles, but also incorporate efficiencies in study design and certainty of decision-making. The purpose of this article is not to restate information that has been provided in earlier FIH guidance documents, but to highlight the new recommendations being suggested.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Bradley Joblin has a doctorate from the University of Zurich, Switzerland. Having held senior management and director positions in clinical research at the headquarters of global pharmaceutical companies and smaller biotechnology companies, his experience is in clinical study implementation, early and late phase clinical study design, and clinical development strategy. Brad founded his own company providing clinical study and development advice to the clinical research community including biotech companies and medical research institutes. He joined Q-Pharm at the start of 2017 to offer scientific oversight and management within Q-Pharm, as well as study design and development strategies to clients.
spacer
Bradley Joblin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

RSSL introduces same-day mycoplasma testing service in UK

RSSL

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement